6618.HK
JD Health International Inc. [6618.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
6618.HK Stock Summary
Top 10 Correlated ETFs
6618.HK
Top 10 Correlated Stocks
6618.HK
In the News
6618.HK Financial details
Company Rating
Buy
Market Cap
161.86B
Income
447.39M
Revenue
53.96B
Book val./share
-7.01
Cash/share
16.88
Dividend
-
Dividend %
-
Employees
2.74K
Optionable
No
Shortable
Yes
Earnings
23 Aug 2023
P/E
323.59
Forward P/E
-
PEG
-23.05
P/S
2.73
P/B
-6.6
P/C
3.02
P/FCF
21.81
Quick Ratio
2.85
Current Ratio
3.45
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.14
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
41.74%
Revenue Q/Q
2.58%
EPS Q/Q
2.47%
-
-
-
-
SMA20
-7.79%
SMA50
-16.74%
SMA100
-30.26%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-7%
ROC
-
Gross Margin
21%
Oper. Margin
-
Profit Margin
1%
Payout
-
Shs Outstand
3.18B
Shs Float
1.01B
-
-
-
-
Target Price
-
52W Range
39.3-90.75
52W High
-43.44%
52W Low
+30.51%
RSI
48.83
Rel Volume
1.12
Avg Volume
6.26M
Volume
7M
Perf Week
5.49%
Perf Month
-9.27%
Perf Quarter
-43%
Perf Half Y
-36.06%
-
-
-
-
Beta
0.542259
-
-
Volatility
0.94%, 2.67%
Prev Close
0.3%
Price
50.9
Change
-0.68%
6618.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 2.61 | 3.47 | 8.78 | 9.91 | 0 | |
| Net income per share | 0.07 | -0.31 | -7.8 | -0.35 | 0 | |
| Operating cash flow per share | 0.06 | 0.13 | 1.68 | 1.11 | 0 | |
| Free cash flow per share | 0.06 | 0.13 | 1.66 | 0.94 | 0 | |
| Cash per share | 0.01 | 2.03 | 18.25 | 13.57 | 0 | |
| Book value per share | 0.24 | -0.15 | 17.77 | 12.88 | 0 | |
| Tangible book value per share | 0.24 | -0.15 | 17.77 | 12.88 | 0 | |
| Share holders equity per share | 0.24 | -0.15 | 17.77 | 12.88 | 0 | |
| Interest debt per share | 0 | 0.01 | 0.04 | 0.07 | 0 | |
| Market cap | 299.52B | 306.81B | 276.55B | 156.1B | 0 | |
| Enterprise value | 299.51B | 301.85B | 244.37B | 139.05B | -21.18B | |
| P/E ratio | 1.39K | -315.71 | -16.05 | -145.51 | 0 | |
| Price to sales ratio | 36.67 | 28.3 | 14.27 | 5.09 | 0 | |
| POCF ratio | 1.6K | 749.27 | 74.75 | 45.5 | 0 | |
| PFCF ratio | 1.62K | 759.83 | 75.55 | 53.6 | 0 | |
| P/B Ratio | 399.78 | -668.38 | 7.05 | 3.92 | 0 | |
| PTB ratio | 399.78 | -668.38 | 7.05 | 3.92 | 0 | |
| EV to sales | 36.66 | 27.84 | 12.61 | 4.53 | -0.45 | |
| Enterprise value over EBITDA | 944.73 | -382.13 | -14.34 | -175.13 | -22.45 | |
| EV to operating cash flow | 1.6K | 737.18 | 66.05 | 40.53 | -3.59 | |
| EV to free cash flow | 1.62K | 747.56 | 66.75 | 47.74 | -5.83 | |
| Earnings yield | 0 | 0 | -0.06 | -0.01 | 0 | |
| Free cash flow yield | 0 | 0 | 0.01 | 0.02 | 0 | |
| Debt to equity | 0 | -0.02 | 0 | 0.01 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -0.04 | 6.27 | 1.89 | 21.48 | -22.45 | |
| Current ratio | 2.71 | 5.58 | 9.12 | 5.71 | 3.45 | |
| Interest coverage | 2.05K | -22.46 | -5K | -142.88 | 88.26 | |
| Income quality | 0.87 | -0.42 | -0.21 | -3.2 | 15.41 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.13 | 0.12 | 0.13 | 0.18 | 0.05 | |
| Research and developement to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.01 | -0.01 | -0.01 | -0.15 | -0.38 | |
| Capex to revenue | 0 | 0 | 0 | -0.02 | -0.05 | |
| Capex to depreciation | -0.39 | -0.77 | -1.42 | -8.2 | -16.16 | |
| Stock based compensation to revenue | 0 | 0 | 0.02 | 0.08 | 0.05 | |
| Graham number | 0.61 | 1.01 | 55.86 | 10.02 | 0 | |
| ROIC | 0.27 | 0.55 | 0.73 | -0.13 | -0.01 | |
| Return on tangible assets | 0.18 | -0.11 | -0.39 | -0.02 | -0.15 | |
| Graham Net | 0.05 | -0.68 | 16.49 | 11.43 | 0 | |
| Working capital | 735.82M | 7.08B | 38.02B | 37.7B | 45.37B | |
| Tangible asset value | 746.46M | -459.63M | 39.22B | 39.83B | -21.23B | |
| Net current asset value | 733.41M | -511.67M | 37.96B | 37.56B | 45.22B | |
| Invested capital | 0 | -0.02 | 0 | 0.01 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 256.44M | 392.61M | 1.67B | 4.19B | 9.05B | |
| Average inventory | 999.67M | 1.2B | 1.51B | 2.39B | 4.91B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 20.06 | 20.23 | 73.17 | 85.25 | 124.92 | |
| Days of inventory on hand | 65.76 | 58.11 | 43.71 | 47.27 | 67.23 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 18.19 | 18.05 | 4.99 | 4.28 | 2.92 | |
| Inventory turnover | 5.55 | 6.28 | 8.35 | 7.72 | 5.43 | |
| ROE | 0.29 | 2.12 | -0.44 | -0.03 | -0.02 | |
| Capex per share | 0 | 0 | -0.02 | -0.17 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
| Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 2.48 | 3.91 | 3.71 | 4.67 | 4.79 | |
| Net income per share | -0.09 | 0.04 | 0.04 | 0.03 | 0.03 | |
| Operating cash flow per share | 0.28 | 0.44 | 0.41 | 0.64 | 0.66 | |
| Free cash flow per share | 0.24 | 0.43 | 0.41 | 0.64 | 0.66 | |
| Cash per share | 13.57 | 16.12 | 14.31 | 16.45 | 16.88 | |
| Book value per share | 12.88 | -7.53 | 13.26 | -6.83 | -7.01 | |
| Tangible book value per share | 12.88 | -4.07 | 13.26 | -6.61 | -6.78 | |
| Share holders equity per share | 12.88 | -7.53 | 13.26 | -6.83 | -7.01 | |
| Interest debt per share | 0.07 | -0.04 | 0.02 | -0.08 | -0.08 | |
| Market cap | 156.1B | 124.58B | 167.64B | 127.91B | 199.14B | |
| Enterprise value | 139.05B | 103.99B | 151.17B | 107.26B | 177.95B | |
| P/E ratio | -145.51 | 226.15 | 321.01 | 361.69 | 548.93 | |
| Price to sales ratio | 20.35 | 9.97 | 14.15 | 8.75 | 13.27 | |
| POCF ratio | 182 | 89.4 | 126.89 | 63.54 | 96.44 | |
| PFCF ratio | 214.38 | 90.25 | 128.11 | 63.87 | 96.94 | |
| P/B Ratio | 3.92 | -5.18 | 3.96 | -5.98 | -9.08 | |
| PTB ratio | 3.92 | -5.18 | 3.96 | -5.98 | -9.08 | |
| EV to sales | 18.13 | 8.32 | 12.76 | 7.33 | 11.86 | |
| Enterprise value over EBITDA | -700.53 | 1.68K | 2.58K | -1.21K | -1.95K | |
| EV to operating cash flow | 162.12 | 74.62 | 114.42 | 53.28 | 86.18 | |
| EV to free cash flow | 190.97 | 75.33 | 115.52 | 53.56 | 86.63 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0.01 | 0.01 | 0.02 | 0.01 | |
| Debt to equity | 0.01 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 85.9 | -333.2 | -281.19 | 232.55 | 232.55 | |
| Current ratio | 5.71 | 4.88 | 4.88 | 3.45 | 3.45 | |
| Interest coverage | -227.65 | -0.67 | -0.67 | 0.29 | 0.29 | |
| Income quality | -3.2 | 10.09 | 10.09 | 23.31 | 23.31 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.25 | 0.05 | 0.05 | 0.04 | 0.04 | |
| Research and developement to revenue | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.15 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Capex to revenue | -0.02 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -8.2 | -0.42 | -0.42 | -0.21 | -0.21 | |
| Stock based compensation to revenue | 0.08 | 0.05 | 0.05 | 0.04 | 0.04 | |
| Graham number | 5.01 | 2.7 | 3.49 | 2.08 | 2.14 | |
| ROIC | -0.05 | 0 | 0 | 0 | 0 | |
| Return on tangible assets | -0.01 | -5.65 | 0 | -0.04 | -0.04 | |
| Graham Net | 11.43 | 12.76 | 11.59 | 11.7 | 12 | |
| Working capital | 37.7B | 49.73B | 40.25B | 44.23B | 45.37B | |
| Tangible asset value | 39.83B | -12.98B | 42.33B | -20.7B | -21.23B | |
| Net current asset value | 37.56B | 49.57B | 40.12B | 44.08B | 45.22B | |
| Invested capital | 0.01 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 3.43B | 7.41B | 8.2B | 9.68B | 12.45B | |
| Average inventory | 1.9B | 3.76B | 4.05B | 5.12B | 6.7B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 84.08 | 86.11 | 68.68 | 95.35 | 95.35 | |
| Days of inventory on hand | 46.62 | 41.3 | 35.26 | 51.31 | 51.31 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.07 | 1.05 | 1.31 | 0.94 | 0.94 | |
| Inventory turnover | 1.93 | 2.18 | 2.55 | 1.75 | 1.75 | |
| ROE | -0.01 | -0.01 | 0 | 0 | 0 | |
| Capex per share | -0.04 | 0 | 0 | 0 | 0 |
6618.HK Frequently Asked Questions
What is JD Health International Inc. stock symbol ?
JD Health International Inc. is a CN stock and trading under the symbol 6618.HK
What is JD Health International Inc. stock quote today ?
JD Health International Inc. stock price is $50.9 today.
Is JD Health International Inc. stock public?
Yes, JD Health International Inc. is a publicly traded company.
Company Profile
- Volume Average 6.26M
- Market Capitalization 161.86B
- Employee 2.74K
- CEO Mr. Enlin Jin
- Headquarters Beijing,CN
- IPO Date 2020-12-08
-
Website
https://ir.jdhealth.com 
JD Health International Inc., an investment holding company, operates an online healthcare platform in the People's Republic of China. It offers pharmaceutical and healthcare products, including OTC drugs, prescription drugs, and medical devices and supplies, as well as health supplements and tonics through direct selling and an online retail pharmacy network. The company also provides online healthcare services, online consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services; health management and intelligent healthcare solutions, as well as technical and advertising services. In addition, it offers access to medical checkups, medical aesthetics, vaccination appointments, dental care services, and nucleic acid testing tests. The company was incorporated in 2018 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. is a subsidiary of JD Jiankang Limited.
